WuXi XDC Cayman, Inc. · HKEX:2268
WuXi XDC Cayman — WuXi XDC — Technical Presentation (July 2024)
21 slides from WuXi XDC Cayman's technical presentation, July 2024
Slide 1: Antibody–Oligonucleotide Conjugates Landscape and WuXi XDC's Capabilities in AOCs
Antibody–Oligonucleotide Conjugates Landscape and WuXi XDC’s Capabilities in AOCs WuXi XDC Jul, 2024
Slide 2: Antibody–Oligonucleotide Conjugates (AOC) Landscape
Antibody–Oligonucleotide Conjugates (AOC) Landscape
Slide 3: What are Antibody–Oligonucleotide Conjugates?
What are Antibody–Oligonucleotide Conjugates? ❑ Antibody–oligonucleotide conjugates (AOCs) combine the high precision of small interfering RNA (siRNA) and anti-sense oligonucleotides (ASO) with the deliverability of antibodies, thus synergizing the advantages of both technologies. ❑ Although siRNA a
Slide 4: Major Advantages of AOCs
Major Advantages of AOCs As compared to oligonucleotides • Better selectivity • Better stability • Better transmembrane properties As compared to LNP • Simpler components • Better targeting As compared to GalNAc • More diverse targets to select Source of the picture regarding AOC structure: Wikipedi
Slide 5: Competitive landscape of AOC field
Competitive landscape of AOC field Preclinical Phase 1/2 Phase 2 Phase 3 30+ AOCs 4 AOCs 1 AOC 1 AOC Others DMD; FSHD; Cancer; Cardiovascular Diseases; Metabolic Myotonic dystrophy type 1 (DM1); Duchenne Muscular Indications: Disorders; Atrophy; Pompe Disease; Spinal muscular atrophy; Dystrophy (DMD
Slide 6: Selected AOCs in Clinical Trials
Selected AOCs in Clinical Trials Antibody Therapeutic Drug Sponsor Tissue target Indication Status properties payload AOC 1001 Avidity TfR1-targed mAb DMPK siRNA Muscle DM1 Phase 3 Exon-44-skipping AOC 1044 Avidity TfR1-targed mAb Muscle DMD Phase 2 PMO AOC 1020 Avidity TfR1-targed mAb DUX4 siRNA Mu
Slide 7: Avidity Biosciences: a Pioneer Company in AOCs
Avidity Biosciences: a Pioneer Company in AOCs o Avidity’s successful pivotal clinical trial proved finally the concept of AOCs o Initiated in May 2024 global Phase 3 HARBOR™ trial of AOC 1001 o Avidity and BMS signed in November 2023 a $2.3bn deal for cardiovascular targets. Source: official websit
Slide 8: General Methods to Conjugate Oligonucleotides
General Methods to Conjugate Oligonucleotides Random Conjugations Site Specific Conjugations Cysteine ThiomAb Nanobody V DAR2 H H BsAb Lysine DAR1
Slide 9: WuXi XDC's Capabilities in AOCs and Beyond
WuXi XDC’s Capabilities in AOCs and Beyond
Slide 10: WuXi XDC Has Extensive Experience On Diverse AOCs
WuXi XDC Has Extensive Experience On Diverse AOCs Delivered 400+ AOC Products Scale: 1mg~100g Conjugation Multiple Conjugation methods Comprehensive Purification / Characterization methods
Slide 11: Case 1: One Conjugation to Get Two AOCs With Two Different DAR values
Case 1: One Conjugation to Get Two AOCs With Two Different DAR values Simultaneously for Further Evaluation Step 1 Step 2 Deblocking Partial Conjugation with Oligo DAR2 + Separation/Purification Thiomab Thiomab NEM DAR1 ❑ This project was at discovery stage, and the client had to assess which DAR va
Slide 12: Case 2: Comprehensive Purification Toolbox to Remove Different AOC Impurities
Case 2: Comprehensive Purification Toolbox to Remove Different AOC Impurities AOC with different oligos have different impurity profiles. Different oligos AOC HPLC Profile of crude High purity products Comprehensive AOC Purification Toolbox
Slide 13: Case 3: A Finished Integrated AOC Discovery Project
Case 3: A Finished Integrated AOC Discovery Project Discussion for the AOC generation for in Larger scale AOC NHP tox study Lead Selection for conjugation strategy Vitro and in Vivo preparation CMC studies • Multiple conjugation • 15+ AOCs at mg scale • 2 AOCs at 4g scale • NHP tox completed • One L
Slide 14: WuXi XDC's Capabilities in broader Bioconjugates
WuXi XDC’s Capabilities in broader Bioconjugates
Slide 15: WuXi XDC Integrated One-Stop CRDMO Service
WuXi XDC Integrated One-Stop CRDMO Service Antibody Discovery Conjugation Research CMC Development IND Filing Commercial Manufacturing Discovery Process Development Payload & Linker Manufacturing An integrated ADC Discovery Industry-leading Process Payload-Linker Integrated Service o Bio-conjugate M
Slide 16: WuXi XDC's Expertise is Much More Than in AOCs
WuXi XDC’s Expertise is Much More Than in AOCs Bioconjugate Modules Native mAb: IgG1, IgG2, IgG4 Antibody Engineered mAb: ThiomAb, NNAA THIOMAB™ NNAA Enzyme-assisted ADC Bi-specific mAb, Nanobody etc. Small molecule linker-payloads LP (Highly potent & non-potent), Dual payloads Radioisotope chelator
Slide 17: Integrated ADC/Bioconjugate Discovery Service from Concept to PCC
Integrated ADC/Bioconjugate Discovery Service from Concept to PCC Binding, Internalization, In Antibody lead • Payload-linker library: vcMMAE, MC- vitro killing, Plasma/Serum identification, MMAF, SMCC-DM1, SPBD-DM4, GGFG- Stability, Metabolite ID optimization and DXd, CL2A-SN38, Tesirine, etc. prod
Slide 18: WuXi XDC's Proprietary Technology- WuXiDAR4
WuXi XDC’s Proprietary Technology- WuXiDAR4TM D4 D2 D0 D6 D8 Highly Compatible with Meet clients’ Simple CMC and homogenous ADC native mAb diversified needs Cost Saving • ≥ 65% of • No antibody • Compatible with • Simple conjugation a single conjugated engineering common linker- process. species wit
Slide 19: Contact Information
Contact Information You are welcome to contact us via the following email or link if you are interested in our company’s service in discovery, development and manufacturing of AOCs and other conjugates. Email:wuxixdc_info@wuxibiologics.com https://wuxixdc.com/contact-us/
Slide 20: Our Mission
Our Mission To accelerate and transform the discovery, development and manufacturing of bioconjugates through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide.
Slide 21: Thanks!
STRONGER AS WuxXi XDC - Your One-Stop Antibody Drug Conjugate (ADC) Development Solution Source: Platform: Team: + Payload-linker + ADCDiscovery __« Service & Support + Antibody + ADC Technology + Product Management Platform + Conjugate + CMC Development + Project Accountability +44 + Drug Product »